Sixth Acquisition Extends Veranex’s Leadership in MedTech Industry Services | Business

RALEIGH, NC – (BUSINESS WIRE) – Dec. 7 2021–

Veranex, the only global provider of technology product development services focused on the medical technology industry, today announced its latest acquisition, Worrell, further expanding its offerings and geographic reach. As an integrated company, Veranex offers compelling strategic, operational and financial advantages by combining the skills and expertise necessary to develop cutting-edge medical technologies, from concept to commercialization. Veranex is the product of six complementary acquisitions backed by growth investor Summit Partners: Ximedica, Quartesian, Boston Healthcare Associates, Experien Group, IMM Research and now Worrell.

This press release features multimedia. View the full release here:

“The addition of Worrell strengthens Veranex’s offerings as the world’s leading supplier of medical devices and biotechnology. By enhancing our human-centered design capabilities with a focus on Phase 0 strategy, design conceptualization and human factors services, we complement our engineering and manufacturing capabilities at the existing ISO-certified pilot scale, ”said Patrick Donnelly, executive chairman of Veranex. . “We are delighted to welcome the Worrell employees to Veranex,” added CEO David Dockhorn. “Kai Worrell joins Veranex as president of our product development and engineering business unit, with sites in Minneapolis, Providence, the San Francisco Bay Area, London and Shanghai. “

“The integration of Worrell into Veranex is timely,” added Kai Worrell. “As the global leaders in medical devices and biotechnology fuel their R&D pipelines, they need world-class partners more than ever. Adding Worrell’s 46 years of design expertise to the power of the Veranex industry will create new opportunities to improve global health outcomes.

Technology Holdings served as financial advisor to Worrell for this transaction, and Saul, Ewing, Arnstein & Lehr LLP acted as their legal advisor. McGuire Woods was legal counsel to Veranex. Financial terms of the transaction were not disclosed.

Veranex has offices on four continents staffed with top designers and engineers as well as market access, regulatory, quality and clinical experts providing support for the full development of MedTech which includes:

  • Product design and engineering
  • Medical device assessment services
  • Clinical development services
  • Data management and analysis
  • Regulatory Affairs and Quality Management
  • Business strategy and market access

Veranex also brings extensive experience in a variety of clinical areas including cardiovascular disease, women’s health, oncology and ophthalmology, as well as expertise in a range of technologies, from screening tests to therapeutic implants and monitoring devices.

Learn more about the complete end-to-end journey it takes to bring medical devices to market on the new Veranex company website.

About Véranex

Veranex is the only truly comprehensive, global and technology-based service provider dedicated to the medical technology industry. Offering expert advice from concept to commercialization and across the development continuum, Veranex enables accelerated time to market, controlled development costs, development risk mitigation and accelerated assessment of market viability. . At every step, Veranex customers realize cost and time savings while its integrated and comprehensive solutions unify the entire development process. For more information, visit

See the source version on

CONTACT: Jane Byram

SCORR Marketing


[email protected]



SOURCE: Véranex

Copyright Business Wire 2021.

PUB: 07/12/2021 9:00 a.m. / DISC: 07/12/2021 9:03 a.m.

Copyright Business Wire 2021.

Previous Competition between the United States and China: What Really Matters?
Next Test the Eating Plan in the Works for Hungry Florida Manatees News from USA®